research

Autolus Therapeutics plc (AUTL) Q4 2025 Earnings Call Transcript

Seeking Alpha

2 min read

0 likes

⚡ Quantum Brief

Autolus Therapeutics reported Q4 2025 earnings, highlighting the commercial launch of AUCATZYL, its CAR-T therapy for adult ALL, now available in the U.S. and U.K. after regulatory approvals. CEO Christian Itin emphasized manufacturing scale-up and sales expansion for AUCATZYL, targeting broader market penetration in 2026 with optimized production capacity. The company provided updates on obe-cel, its lead candidate for B-cell malignancies, noting ongoing Phase 3 trials and potential regulatory submissions by late 2026. CFO Robert Dolski outlined financial strategies, including cost controls and partnerships, to sustain R&D investments amid AUCATZYL’s commercial rollout and pipeline growth. Analysts questioned clinical timelines, market adoption, and pricing strategies, with management reaffirming confidence in AUCATZYL’s long-term revenue potential.

AI Audio Summary

0:00 / 0:00

Click to play

Quantum News · Media Library

Understand this faster with AI

Ask ChatGPT

Research with Perplexity

Explain with Claude

Discuss on Grok

SA Transcripts159.13K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Autolus Therapeutics plc (AUTL) Q4 2025 Earnings Call March 27, 2026 8:30 AM EDT Company Participants Amanda Cray - Executive Director of Investor Relations & External CommunicationsChristian Itin - CEO & DirectorRobert Dolski - Senior VP & CFO Conference Call Participants James Shin - Deutsche Bank AG, Research DivisionGil Blum - Needham & Company, LLC, Research DivisionSalim Syed - Mizuho Securities USA LLC, Research DivisionMatthew Phipps - William Blair & Company L.L.C., Research DivisionYanan Zhu - Wells Fargo Securities, LLC, Research DivisionEmily Bodnar - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Autolus Fourth Quarter 2025 and Full Year 2025 Financial Results Conference Call. [Operator Instructions] Please be advised today's conference is being recorded. I would now like to hand the conference over to your speaker today, Amanda Cray, Executive Director of Investor Relations. Please go ahead. Amanda CrayExecutive Director of Investor Relations & External Communications Thank you, Kevin. Good morning or good afternoon, everyone, and thank you for joining us on today's call. With me are Chief Executive Officer, Dr. Christian Itin; and Chief Financial Officer, Rob Dolski. On Slide 2, I'd like to remind you that during today's call, we will make statements related to our business that are forward-looking under federal securities laws and the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These may include, but are not limited to, statements regarding status of the ongoing commercial launch of AUCATZYL in the U.S. and U.K., Autolus manufacturing, sales and marketing plans for AUCATZYL, the market potential for AUCATZYL and the status of clinical trials, development and/or regulatory time lines and market opportunities for obe-cel and our other product candidates. These statements are subject to a variety of

Read Original

Source Information

Source: Seeking Alpha

Website: https://seekingalpha.com/feed.xml

Discussion

0 professional contributions

Be the first to add a constructive contribution.